Parent company of Thronton & Ross acquires Parkinson’s disease therapy

STADA has snapped up Lobsor Pharmaceuticals, has gained the rights to a triple fixed combination, levodopa, carbidopa and entacapone, delivered through modern pump technology,

Peter Goldschmidt, CEO of STADA, said: “This acquisition of Lobsor significantly expands STADA’s specialty footprint and serves as further evidence that STADA is a leading go-to-partner for specialty pharmaceuticals, generics and consumer health products.

“It also complements our portfolio and expertise in the treatment of late-stage Parkinson’s disease, where we have strong expertise via our company Britannia Pharmaceuticals headquartered in Reading.”

STADA is the parent company of Thornton & Ross, which employs more than 500 people at its headquarters in Huddersfield. The firm offers a wide and diverse portfolio of generic pharmaceuticals and over the counter healthcare solutions.

---

Support The Yorkshire Post and become a subscriber today.

Your subscription will help us to continue to bring quality news to the people of Yorkshire. In return, you'll see fewer ads on site, get free access to our app and receive exclusive members-only offers.

So, please - if you can - pay for our work. Just £5 per month is the starting point. If you think that which we are trying to achieve is worth more, you can pay us what you think we are worth. By doing so, you will be investing in something that is becoming increasingly rare. Independent journalism that cares less about right and left and more about right and wrong. Journalism you can trust.

Thank you

James Mitchinson